Thermo Fisher Scientific (NYSE:TMO) Given New $590.00 Price Target at Evercore ISI

Key Points

• Evercore ISI has raised the price target for Thermo Fisher Scientific from $525.00 to $590.00, indicating a potential upside of 9.35% from the company's previous close and maintaining an "outperform" rating.
• Thermo Fisher announced a quarterly earnings report with earnings per share (EPS) of $5.36, surpassing analysts' estimates, along with a revenue of $10.86 billion, marking a 2.9% increase year-over-year.
• After recent trading, Thermo Fisher Scientific's stock price fell by 0.8% to $539.55, with various analysts offering mixed ratings and price targets on the stock.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price target boosted by Evercore ISI from $525.00 to $590.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an "outperform" rating on the medical research company's stock. Evercore ISI's price target suggests a potential upside of 9.35% from the company's previous close.

A number of other analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. UBS Group lifted their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research note on Saturday, September 27th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research note on Friday, July 11th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $591.16.

Thermo Fisher Scientific Stock Down 0.8%

Shares of Thermo Fisher Scientific stock traded down $4.40 during trading on Tuesday, hitting $539.55. The company's stock had a trading volume of 1,200,201 shares, compared to its average volume of 2,435,758. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a fifty day simple moving average of $483.77 and a two-hundred day simple moving average of $446.95. The company has a market capitalization of $203.74 billion, a PE ratio of 31.21, a P/E/G ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific will post 23.28 earnings per share for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last quarter. Insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

Several hedge funds have recently modified their holdings of the company. CBIZ Investment Advisory Services LLC raised its position in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $30,000. Capital A Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 825.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock valued at $30,000 after purchasing an additional 66 shares during the last quarter. Keystone Global Partners LLC purchased a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. Finally, DiNuzzo Private Wealth Inc. raised its position in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock worth $31,000 after buying an additional 61 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.